BioTuesdays

Tag - FLKS

Flex Pharma

Ladenburg ups Flex Pharma PT to $20 from $13

Ladenburg Thalmann raised its price target for Flex Pharma (NASDAQ:FLKS) to $20 from $13 after the company announced that its lead asset, FLX-787, reduced the frequency of cramps/spasms in a 57-patient, placebo...

Flex Pharma focused on 3 clinical readouts in 2018

By Len Zehr Flex Pharma (NASDAQ:FLKS) expects to report clinical readouts in 2018 from three Phase 2 studies of its anti-cramping drug candidate, FLX-787, in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth...

Flex Pharma

Flex Pharma starts Phase 2 CMT trial

Flex Pharma (NASDAQ:FLKS) has initiated a Phase 2 double-blinded, parallel design trial in the U.S., known as COMMIT, to evaluate FLX-787, its co-activator of TRPA1 and TRPV1, in patients with Charcot-Marie-Tooth, who...